



Early View

Research letter

Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD

Jørgen Vestbo, Grant Waterer, David Leather, Courtney Crim, Nawar Diar Bakerly, Lucy Frith, Loretta Jacques, Catherine Harvey, Imran Satia, Ashley Woodcock

Please cite this article as: Vestbo J, Waterer G, Leather D, *et al.* Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD. *Eur Respir J* 2022; in press (<https://doi.org/10.1183/13993003.02899-2021>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org

Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD

Jørgen Vestbo, DMSc,¹ Grant Waterer,² David Leather, MB ChB,³ Courtney Crim, MD,⁴ Nawar Diar Bakerly, MD,⁵ Lucy Frith, MSc,⁶ Loretta Jacques, PhD,⁶ Catherine Harvey, DPhil,⁷ Imran Satia, PhD,^{1,8} Ashley Woodcock, MD,¹ on behalf of the Salford Lung Study

Investigators

1. Division of Infection, Immunity and Respiratory Medicine, The University of Manchester, and Manchester University NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK
2. University of Western Australia and Northwestern University, Chicago
3. Global Respiratory Franchise, GlaxoSmithKline UK Ltd, Brentford, UK
4. Clinical Sciences, GSK, Research Triangle Park, NC, USA
5. Salford Royal NHS Foundation Trust, Salford, UK
6. Respiratory Research and Development, GlaxoSmithKline UK Ltd, Brentford, UK
7. Global Clinical Safety & Pharmacovigilance, Safety Evaluation and Risk Management, GlaxoSmithKline UK Ltd, Uxbridge, UK
8. McMaster University Hamilton, Ontario, Canada

Corresponding author:

Professor Jørgen Vestbo
2nd Floor, ERC Building
Wythenshawe Hospital
Southmoor Road
Manchester, M23 9LT
United Kingdom
Tel: +45 3035 0317
Email: jorgen.vestbo@manchester.ac.uk

Running Head: Fatal pneumonias and exacerbations in COPD

Trial Registration: NCT01551758

Sponsor: GlaxoSmithKline
Funder: GlaxoSmithKline

Word count: 1194, 1 figure

Keywords: COPD; effectiveness; exacerbations; pneumonia; mortality; fluticasone furoate; vilanterol; combination therapy.

Patients with chronic obstructive pulmonary disease (COPD) often experience exacerbations and pneumonia that are occasionally severe and lead to hospital admission (1-3). The risk of pneumonia is further increased by treatment with inhaled corticosteroids (ICS) (4-6).

Although potentially difficult to distinguish (7), there could be differences in the risk of death associated with these events that need to be taken into account when planning management and clinical follow-up. The Salford Lung Study (SLS) was set up to evaluate the effectiveness and safety of the once-daily inhaled combination of fluticasone furoate and vilanterol (FF/VI in ELLIPTA DPI) compared with existing maintenance therapy (usual care) in a large, real-world population of patients with COPD in conditions of normal care (8).

Strengths of the study include the relatively unselected patient population, the completeness of follow-up using a joint electronic record system and the fact that all patients were provided usual standard of care for their exacerbations and during admissions. We used this study database to examine mortality after an admission with a severe exacerbation or pneumonia, and the impact of classification of these events.

A total of 2,799 patients who were 40 years or older, had a documented diagnosis of COPD made by a general practitioner (GP) and ≥ 1 COPD exacerbations in the last 3 years were recruited from general practice for the Salford Lung Study (8). All patients were on regular maintenance inhaler therapy.

The study has been described in detail previously (8). Mean age and FEV₁ were 67 years and 1.62 liters and 49% were women. In the analyses for this sub-study, we have pooled all ICS patients to be able to jointly analyse a sufficient number of events. We reviewed narratives of all deaths as well as all chest radiographs available in the study period for patients being admitted with either a severe exacerbation or a pneumonia. Radiographs were ordered at the clinicians' discretion. For this study, the radiographs were all read by three specialist

radiologists independently and unaware of the physicians' diagnoses. In case of disagreement, consensus was found through discussion.

To ensure sufficient follow-up after events, we included events up to 184 days after randomisation in order to have 6 months of follow-up. A severe exacerbation was defined as hospital admission and a diagnosis of an exacerbation. An admission with pneumonia was based on the initial diagnosis made by the treating physician. For our additional classification analysis, we assigned a diagnosis based on the radiologist's evaluation of the chest radiograph; i.e., presence vs absence of a new lung infiltrate; pneumonia vs exacerbation. We used first hospital admission for either of these events. For this, we had access to 121 chest radiographs, all evaluated by three radiologists.

Of the 2,799 patients who underwent randomization, 111 patients experienced a hospital admission with an initial diagnosis of a COPD exacerbation, 86 were hospitalised with an initial diagnosis of pneumonia. Patients admitted were older (Pneumonia: 70.2 years, COPD exacerbation: 69,3 years) than those not admitted (66.4 years). Patients admitted with pneumonia were more often men and less often current smokers when comparing with patients admitted for a COPD exacerbation or not admitted with either. Of those admitted with COPD 60% had severe or very severe COPD, this was the case for 47% of those admitted with pneumonia and 27% among those not admitted. Both a history of >2 exacerbations during the year prior to randomisation and cardiac comorbidity were more frequent for those admitted with COPD (77% and 47%) compared to those with pneumonia (53% and 42%) and those not admitted (48% and 30%).

Of the 111 with a hospitalized exacerbation, 8 (7%) died during the 6 months follow-up whereas this was the case for 14 (16%) of the 86 with a pneumonia admission. In a Cox regression model with age, sex, exacerbation history, use of ICS at study entry, score from the COPD Assessment Test, and smoking status as covariates, hazard ratios for mortality

within 30 days of being hospitalised were 29.6 (95% confidence interval 12.5-69.9) and 176.8 (102.6-304.7) for an exacerbation admission and a pneumonia admission, respectively.

In a similar model analysing mortality 31-180 days following hospital admission, hazard ratios were 0.85 (0.1-6.2) and 11.6 (5.1-26.3), respectively. Exacerbation history prior to admission did not differ among those dying from an exacerbation or a pneumonia.

There was a substantial discrepancy between events diagnosed as a pneumonia by the admitting physician and the subsequent classification of events based on a blinded specialist radiologists' evaluation of a chest x-ray. Radiologists agreed on the presence of pneumonia in only 61% of cases and 10 cases clinically classified an acute exacerbation of COPD were reclassified as pneumonia. Radiologist reclassification of the presence or absence of pneumonia had a significant impact on the risk of death after discharge (figure 1).

Interpretation of mortality following an admission comes with caveats. Many deaths occurred months following the index hospitalisation, something that is well known from previous studies of pneumonia. However, the risk of death continued to rise for approximately 3 months. We had 6 months follow-up and it is possible that longer follow-up may have added additional excess deaths. Malignancies were frequent in this patient group as in COPD in general, and we cannot preclude the possibility that some of the pneumonias were the first impact of a subsequently fatal malignancy. It is, nevertheless, noteworthy that a persistent elevated risk of mortality after 30 days was only observed in patients when independent radiological assessment confirmed the diagnosis of pneumonia. The impact of a radiologist's diagnosis of an infiltrate consistent with pneumonia was significant and important for prognosis. This has implications for clinical care as the importance of a distinction between an exacerbation and a pneumonia is rarely highlighted (1) and is a salient lesson for interpreting past and future studies of pneumonia in the setting of COPD.

Approximately 90% of patients in our sub-study were treated with ICS due to the study design (8). We could therefore not assess the added risk from ICS; however, the risk of pneumonia associated with ICS use is well documented (9). The aim of treating with ICS is to reduce exacerbations requiring treatment with systemic corticosteroids, a treatment in itself associated with an increased risk of severe pneumonia (10). This invariably complicates the assessment of risk/benefit for ICS for the clinician.

Our study included an unselected population of patients with a diagnosis of COPD, likely representing up to 50% of all COPD patients in Salford. In a pragmatic setting, a number of uncertainties exist; e.g., varying use of diagnostic procedures, variation in clinicians' diagnostic evaluation, effect of subsequent readmissions, etc. However, this real-world data is important because interpretation of the risks associated with pneumonia in the setting of ICS treatment in randomized controlled trials is potentially misleading as patients who may be at the highest risk of pneumonia (very low lung function, very low BMI, significant comorbidities) are often excluded. Our data strongly suggests that in an unselected group of patients with COPD, the weighting given to pneumonia events in deciding whether to use ICS or not may be different in some groups of patients, especially those who would typically be excluded from randomized, controlled trials.

Acknowledgments

Trademarks are owned by or licensed to the GlaxoSmithKline group of companies. JV and AW are supported by the NIHR Manchester BRC.

Sources of support

The study was fully funded by GlaxoSmithKline plc. (study number: HZC115151). JV, IS and AW are supported by the National Institute of Health Research Manchester Biomedical

Research Centre (NIHR Manchester BRC). JV received personal fees from GlaxoSmithKline plc., Chiesi Pharmaceuticals, Boehringer-Ingelheim, Novartis and AstraZeneca, congress attendance from Chiesi and holds a grant from Boehringer-Ingelheim; GW received personal fees from GlaxoSmithKline plc.; NB received grants and personal fees from GlaxoSmithKline plc., Novartis and Almirall/AstraZeneca, and congress attendance from Boehringer-Ingelheim; IS received personal fees from GlaxoSmithKline plc., consulting and speaker fees AstraZeneca and Merck, grants from Merck, GlaxoSmithKline plc, fellowship from ERS Marie-Curie Award, E.J.Moran Campbell Early Career Award, Department of Medicine, McMaster, outside the submitted work; AW received speaker fees and expenses from Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, and Novartis; is chairman/shareholder of Reacta Healthcare and Axalbion, and Chairman of the Medicines Evaluation Unit. DL, LF, LJ and CH are employees of GlaxoSmithKline plc. and hold shares in the company, CC was an employee of GlaxoSmithKline plc. at the time of the study.

Data sharing statement

Information on GlaxoSmithKline's data sharing commitments and requesting access to anonymized individual participant data and associated documents can be found at www.clinicalstudydatarequest.com.

References

1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. *Eur Respir J* 2017; 49: 1700214. Available on www.goldcopd.org, last accessed on 15 October 2019.

2. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. *N Engl J Med* 2010; 363: 1128-38.
3. Lange P, Vestbo J, Nyboe J. Risk factors for death and hospitalisation from pneumonia. A prospective study of a general population. *Eur Respir J* 1995; 8: 1694-8.
4. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. *Am J Respir Crit Care Med* 2007; 176: 162-6.
5. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2014; 3: CD010115.
6. Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravittles M, Davis KJ, Wedzicha JA. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. *Respir Med* 2012; 106: 1124-33.
7. Lieberman D, Lieberman D, Gelfer Y, Varshavsky R, Dvoskin B, Leinonen M, Friedman MG. Pneumonic vs nonpneumonic acute exacerbations of COPD. *Chest* 2002; 122: 1264-70.
8. Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice. *N Engl J Med* 2016; 375: 1253-60.
9. Dransfield MT, Crim C, Criner GJ, et al. Risk of Exacerbation and Pneumonia with Single Inhaler Triple Versus Dual Therapy in IMPACT. *Ann Am Thorac Soc* 2020; Oct 27. doi: 10.1513/AnnalsATS.202002-096OC. Online ahead of print. PMID: 33108212

10. Waljee AK Rogers MAM, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. *BMJ* 2017; 357: j1415.

Figure Legend:

Figure 1

Time to death following a hospital admission for an exacerbation or pneumonia for diagnoses according to study reporting (upper panel) and radiologist reporting (lower panel).

